• Ticker

    Advertisement Find a Broker - Visit the DailyFinance Broker Center
DJIA 12,454.83 -74.92 -0.60%
NASDAQ 2,837.53 -1.85 -0.07%
S&P 500 1,317.82 -2.86 -0.22%

$10.43 $0.00 (0.00%)

REAL-TIME: Last trade at

Alnylam Pharmaceuticals, Inc.

NASDAQ:ALNY

Jump to this page for:

Related Resources

Tekmira Provides Periodic Update to Shareholders Regarding Litigation

5/24/2012 by GlobeNewswire

Boston CEO Conference to Feature CEOs of Alkermes, Alnylam, Ariad, Biogen, Cubist, Genzyme, Millennium, Momenta, Sirtris, and Others June 11th and 12th

5/24/2012 by PharmiWeb.com - UK

Boston CEO Conference to Feature CEOs of Alkermes, Alnylam, Ariad, Biogen, Cubist, Genzyme, Millennium, Momenta, Sirtris, and Others June 11th and 12th

5/24/2012 by Business Wire

Alnylam and PBL Sign License Agreement for Baulcombe & Hamilton RNAi Patent

5/23/2012 by Genetic Engineering News

Alnylam and PBL sign license agreement for Baulcombe & Hamilton RNAi patent

5/23/2012 by Theflyonthewall.com

Alnylam and PBL Sign License Agreement for Baulcombe & Hamilton RNAi Patent

5/23/2012 by Business Wire

Tekmira Provides Corporate Update and Announces First Quarter 2012 Results

5/15/2012 by GlobeNewswire

Tekmira client Alnylam provides ALN-TTR01 results

5/10/2012 by StockWatch

Tekmira's LNP Technology Enables Alnylam's ALN-TTR01 Clinical Data

5/10/2012 by GlobeNewswire

Alnylam Pharma (ALNY) Reports Phase 1 Trial Results Show Proof of Concept for ALN-TTR01

5/10/2012 by StreetInsider.com

Alnylam's ALN-TTR01 for ATTR shows positive Phase I results

5/10/2012 by Theflyonthewall.com

Alnylam to Webcast Presentation at Upcoming Investor Conferences

5/9/2012 by Business Wire

Biotechs Bucking The Dendreon Trap & Curse (DNDN, VRTX, VVUS, ARNA, ALNY, AMGN, SVNT)

5/8/2012 by 24/7 Wall Street

JP Morgan's biotech analysts hold a conference call on orphan drug coverage

5/8/2012 by Theflyonthewall.com

Alnylam Steps Back from Huntington's Drug Deal, Sees Two Partnerships by Year-End

5/8/2012 by GenomeWeb

Top Analyst Upgrades & Downgrades (ACM, ALNY, BIIB, BP, COF, SNP, CTSH, EA, EPB, ERJ, F, LPX, MFC, MM, RAX, SYNC, VRTX, WYNN)

5/8/2012 by 24/7 Wall Street

Alnylam initiated with an Overweight at JPMorgan

5/8/2012 by Theflyonthewall.com

Alnylam Narrows Loss - Analyst Blog

5/4/2012 by Zacks Investment Research

Alnylam Narrows Loss

5/4/2012 by Zacks Equity Research Analyst Blog

Alnylam Pharmaceuticals Reports First Quarter 2012 Financial Results

5/4/2012 by PharmiWeb.com - UK

Alnylam expects that its cash, cash equivalents greater than $250M at year end

5/3/2012 by Theflyonthewall.com

Alnylam Pharmaceuticals, Inc. (ALNY) Posts Narrower than Expected Q1 Loss

5/3/2012 by StreetInsider.com

Alnylam reports Q1 GAAP EPS (25c), consensus (36c)

5/3/2012 by Theflyonthewall.com

Regulus Therapeutics Appoints Bruce Carter to its Board of Directors

4/30/2012 by PR Newswire

Alnylam to Webcast Conference Call Discussing First Quarter 2012 Financial Results

4/27/2012 by PharmiWeb.com - UK

Alnylam to Webcast Conference Call Discussing First Quarter 2012 Financial Results

4/26/2012 by Business Wire

Alnylam Elects Dr. Dennis Ausiello to its Board of Directors and Scientific Advisory Board

4/23/2012 by PharmiWeb.com - UK

Regulus Receives Allowance from Japan and U.S. Patent Offices for HCV Intellectual Property, Expanding Leading Worldwide Patent Estate

4/23/2012 by PR Newswire

Alnylam Elects Dr. Dennis Ausiello to its Board of Directors and Scientific Advisory Board

4/23/2012 by Business Wire

Alnylam scores efficacy data with PCSK9 drug

4/20/2012 by Fierce Biotech

Tekmira's LNP Technology Enables Alnylam's Positive ALN-PCS Clinical Data

4/20/2012 by StockHouse

Tekmira's LNP Technology Enables Alnylam's Positive ALN-PCS Clinical Data

4/20/2012 by GlobeNewswire

Alnylam (ALNY) Reports Statiscally Significant Data from ALN-PCS Phase I

4/20/2012 by StreetInsider.com

Drug Information Association to host a conference

4/16/2012 by Theflyonthewall.com

Alnylam to Webcast Presentation at Future Leaders in the Biotech Industry Conference

4/14/2012 by PharmiWeb.com - UK

Alnylam to Webcast Presentation at Future Leaders in the Biotech Industry Conference

4/13/2012 by Business Wire

Tekmira Management Offers Pipeline Update, Reiterates Claim to Disputed Delivery Technology

3/29/2012 by GenomeWeb

IP Update: Recent Patents, Patent Applications Awarded to Alnylam; Whitehead; Merck; and More

3/28/2012 by GenomeWeb

The Zacks Analyst Blog Highlights: Amgen, Sanofi, Regeneron, Alnylam and Coach

3/28/2012 by PR Newswire

The Zacks Analyst Blog Highlights: Amgen, Sanofi, Regeneron, Alnylam and Coach - Press Releases

3/28/2012 by Zacks Investment Research
See More Articles...